Kiran Mazumdar’s biotech empire isn’t just about revenue. It’s about relevance. In a world facing rising healthcare costs and unequal access to life-saving drugs, her model of “affordable excellence” is more urgent than ever. She doesn’t need a slogan. She has a legacy. And it’s growing—molecule by molecule, lab by lab, life by life.
